News: Many Indian companies are looking to invest in Zimbabwe's pharmaceutical industry, New Ziana has reported. Owen Mugurungi, the director of the AIDS and tuberculosis unit ar the Ministry of Health, Children and Welfare said several investors are willing to collaborate with the government to set up plants to produce generic antiretroviral (ARV) drugs. Zimbabwe will benefit from strategic alliances with India and other key emerging markets such as Brazil, Russia and South Africa, said Mugurungi.
BMI View: BMI's Burden of Disease Database (BoDD) estimates the number of disability-adjusted life years (DALYs) lost to HIV/AIDS in Zimbabwe was 4.8mn in 2010. We forecast this will increase by 7.9% to 5.2mn DALYs by 2015 and by 30.6% to 6.7mn DALYs by 2030.